PRA moves profits forward

By Kirsty Barnes

- Last updated on GMT

Related tags: Cent, Revenue

Despite a dip in revenue, PRA International saw its profit grow 53
per cent in the fourth quarter of 2005 to reach $7.5m (€6.3m) on
the back of improved margins. The global clinical research
organization (CRO) also saw a similar growth in full-year profits.

PRA's service revenue took a 2.3 per cent downturn in the fourth quarter, attributed by the company to a delayed execution of three major biotech contracts. The firm also experienced a $2m downturn in new business during the same period.

Despite the drop-off, the company still managed to gain a 53 per cent increase in net profit for the quarter through a 4.3 per cent jump in profit margin.

The full year results were also positive for PRA, who achieved a 55 per cent increase in net income to $32m, after increasing its service revenue by 6 per cent and its profit margin by 4.3 per cent to 17.4.

New business awards for the full year were $479m, up by $52m on 2004. Backlog in business was up 23 per cent.

"We completed our first full year as a public company in 2005 with record financial and operating performance,"​ said Pat Donnelly, PRA International president and CEO.

"We have made significant progress in expanding our global footprint across six continents, opened our newly renovated Phase I facility in Lenexa, Kansas, and dramatically enhanced our technology platform to become more efficient and deliver timely results to our clients,"​ said Donnelly, commenting on the results.

Looking forward into 2006, PRA plans to expand its geographic reach in Asia and Latin America and capture additional market share in cardiovascular and respiratory clinical trials.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars